Acumen Pharmaceuticals announced that the first patient has been dosed with sabirnetug in the ALTITUDE-AD Phase 2 clinical trial designed to evaluate the clinical efficacy and safety of sabirnetug in patients with early AD. “Today marks a significant milestone for Acumen and the Alzheimer’s community as we begin the Phase 2 trial of sabirnetug,” said Daniel O’Connell, Chief Executive Officer of Acumen. “Sabirnetug is at the forefront of the next generation of Alzheimer’s therapies, with encouraging Phase 1 results supporting its novel mechanism of action and selectivity for toxic amyloid beta oligomers. These results have led to a high level of investigator and patient interest in sabirnetug’s therapeutic potential and a strong start to the trial.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABOS:
- Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024
- These 2 ‘Strong Buy’ Penny Stocks Are Poised for Over 300% Gains, Say Analysts
- Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
- Acumen presents first clinical, biomarker data for ACU193
- Acumen teams with Lonza for advancement of sabirnetug to treat AD